The recent Blaze Media article (published around March 22, 2026) highlights a study from Chinese researchers at the Chinese Academy of Sciences, detailing an experimental approach to turn Aedes aegypti mosquitoes into "flying syringes" or "flying vaccines." The goal isn't vaccinating humans directly — it's immunising wild bats, the natural reservoirs for deadly zoonotic viruses like rabies (nearly 100% fatal once symptomatic in humans) and Nipah (40-75% fatality rate). By vaccinating bats en masse, the idea is to reduce spillover risks to people, livestock, or other animals without culling bats (which harms ecosystems and conservation) or trying to jab millions of elusive flying mammals individually. How the "Flying Syringe" System Works (Per the Study) Published in Science Advances (March 11, 2026), the proof-of-concept lab work involved: Creating recombinant vesicular stomatitis virus (rVSV) — a weakened, safe virus platform already used in approved Ebola vaccines (e.g., Ervebo) — engineered to express key surface proteins from rabies or Nipah viruses. Feeding lab mosquitoes blood mixed with this vaccine virus, allowing it to replicate inside them and reach their salivary glands (lasting over two weeks). Releasing these vaccine-carrying mosquitoes to bite test bats (and rodents in controls), delivering the vaccine via saliva during feeding. For fruit bats (which don't typically eat mosquitoes), adding vaccine-laced saline drinking stations as an attractant/trap system. Results: Bats developed strong, protective antibody responses and resisted infection challenges in lab tests. Mosquitoes were sterilised (e.g., via X-rays) to prevent wild breeding. The researchers (including virologist Aihua Zheng) describe it as a "scalable and efficient" ecological vaccination strategy for bat-borne threats, potentially adaptable to other viruses like coronaviruses. This is lab-stage only — no wild field releases mentioned. It's not the same as past "flying syringe" concepts (e.g., 2010s Japanese work for malaria antigens in mosquito saliva for humans/animals, or Gates-funded ideas), which faced huge barriers and were mostly abandoned for human use. Possible Dangers and Concerns of Using Mosquitoes This Way While the approach targets animals (bats) and uses a weakened virus platform, critics and independent experts (like Daniel Streicker from the University of Glasgow, quoted in coverage) highlight serious biosafety, ecological, and ethical risks if scaled up or mishandled. Here's a breakdown of the key potential dangers: Unintended Human Exposure and Non-Target Vaccination Mosquitoes don't discriminate — Aedes aegypti bites humans readily (it's a primary dengue/Zika vector). If released in large numbers near bat habitats, people could get bitten and inadvertently receive the vaccine. This removes informed consent — a core ethical principle in medicine. Streicker noted: "Mosquitoes bite many things other than bats, including humans... There's still an issue that you're removing individual consent." Even a weakened rVSV could cause mild illness, allergic reactions, or rare severe effects in vulnerable people (e.g., immunocompromised). Vaccine Virus Reversion or Recombination Risks rVSV replicates in both insects and mammals. Though engineered to be safe, there's theoretical risk of: Reversion to a more virulent form through mutations. Recombination with wild viruses in bats or mosquitoes, potentially creating novel pathogens (a concern echoed in lab-leak debates around gain-of-function work). The article ties this to broader suspicions about Chinese virology labs (e.g., PLA links, COVID origins theories), amplifying fears of accidental release creating new threats. Ecological Disruption Mass-releasing (even sterilised) mosquitoes could: Alter local insect populations or food webs (bats eat mosquitoes; vaccine carriers might affect bat behaviour or health indirectly). Spread beyond target areas via wind/migration, vaccinating non-target wildlife unpredictably. Interact with existing diseases — e.g., if mosquitoes carry other pathogens naturally. Regulatory, Oversight, and Dual-Use Concerns Deploying this in the wild would require massive international oversight (WHO, biosafety protocols), but China's state-linked research raises questions about transparency. Past mosquito modification programs (e.g., Wolbachia for dengue suppression) have succeeded in controlled releases, but vaccine delivery adds complexity. Efficacy and Long-Term Unknowns Lab success doesn't guarantee wild performance — bats roost in huge colonies across vast areas, with diverse diets/behaviours. Partial vaccination could drive viral evolution (e.g., vaccine escape mutants). Unintended immune effects in bats (e.g., altering viral shedding) remain unstudied. Bottom line: This is innovative One Health thinking — preventing pandemics at the source by targeting reservoirs. But the "flying syringe" label invites dystopian fears, and experts stress it's far from deployment. Any real-world use would need rigorous safety testing, ecological modelling, and global consent frameworks to avoid turning a creative solution into an accidental hazard. If you're in Brisbane (where mozzies are already a summer nuisance), this kind of tech feels especially sci-fi creepy — but right now, it's strictly bats-only in a Chinese lab. Who know how long it will stay that way. https://www.theblaze.com/news/chinese-scientists-have-turned-mosquitoes-into-flying-vaccines-that-can-still-bite-humans